TotarolCAS# 511-15-9 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 511-15-9 | SDF | Download SDF |
| PubChem ID | 326995 | Appearance | Powder |
| Formula | C20H30O | M.Wt | 286.46 |
| Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 4b,8,8-trimethyl-1-propan-2-yl-5,6,7,8a,9,10-hexahydrophenanthren-2-ol | ||
| SMILES | CC(C)C1=C(C=CC2=C1CCC3C2(CCCC3(C)C)C)O | ||
| Standard InChIKey | ZRVDANDJSTYELM-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C20H30O/c1-13(2)18-14-7-10-17-19(3,4)11-6-12-20(17,5)15(14)8-9-16(18)21/h8-9,13,17,21H,6-7,10-12H2,1-5H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Totarol has anti-bacteria effect by restraining bacterial growth by perturbing the cell division and proliferation, including several pathogenic Gram-positive bacteria, mycobacterium tuberculosis. 2. Totarol treatment leads to metabolic shutdown by repressing the major central metabolic dehydrogenases in B. subtilis. |
| Targets | Antifection |
Totarol Dilution Calculator
Totarol Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.4909 mL | 17.4544 mL | 34.9089 mL | 69.8178 mL | 87.2722 mL |
| 5 mM | 0.6982 mL | 3.4909 mL | 6.9818 mL | 13.9636 mL | 17.4544 mL |
| 10 mM | 0.3491 mL | 1.7454 mL | 3.4909 mL | 6.9818 mL | 8.7272 mL |
| 50 mM | 0.0698 mL | 0.3491 mL | 0.6982 mL | 1.3964 mL | 1.7454 mL |
| 100 mM | 0.0349 mL | 0.1745 mL | 0.3491 mL | 0.6982 mL | 0.8727 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Sugiol
Catalog No.:BCN3164
CAS No.:511-05-7
- alpha-Onocerol
Catalog No.:BCN5630
CAS No.:511-01-3
- Nicotine 1'-N-oxide
Catalog No.:BCN6892
CAS No.:51095-86-4
- 2,7-Dihydrohomoerysotrine
Catalog No.:BCN5629
CAS No.:51095-85-3
- Methyl p-hydroxyphenyllactate
Catalog No.:BCN6669
CAS No.:51095-47-7
- Pyrrolidinedithiocarbamate ammonium
Catalog No.:BCC6766
CAS No.:5108-96-3
- Boc-Lys(Z)-pNA
Catalog No.:BCC3419
CAS No.:51078-31-0
- ATC 0175 hydrochloride
Catalog No.:BCC7657
CAS No.:510733-97-8
- ATC 0065
Catalog No.:BCC7666
CAS No.:510732-84-0
- Wogonoside
Catalog No.:BCN1200
CAS No.:51059-44-0
- alpha-Lipomycin
Catalog No.:BCN1842
CAS No.:51053-40-8
- Z-GABA-OH,Z-gama-Abu-OH
Catalog No.:BCC2644
CAS No.:5105-78-2
- Vitamin D4
Catalog No.:BCC2042
CAS No.:511-28-4
- Plumieride
Catalog No.:BCN5631
CAS No.:511-89-7
- Gitogenin
Catalog No.:BCN3886
CAS No.:511-96-6
- 8-Bromo-cGMP, sodium salt
Catalog No.:BCC6935
CAS No.:51116-01-9
- Cyclic Pifithrin-α hydrobromide
Catalog No.:BCC2407
CAS No.:511296-88-1
- (+)-trans-Isolimonene
Catalog No.:BCC9236
CAS No.:5113-87-1
- (S)-(+)-Ibuprofen
Catalog No.:BCC4042
CAS No.:51146-56-6
- (R)-(-)-Ibuprofen
Catalog No.:BCC4062
CAS No.:51146-57-7
- Episyringaresinol
Catalog No.:BCN7023
CAS No.:51152-20-6
- Boc-D-Asp(OBzl)-OH
Catalog No.:BCC3371
CAS No.:51186-58-4
- Withaferin A
Catalog No.:BCC7495
CAS No.:5119-48-2
- Diosgenin
Catalog No.:BCN6272
CAS No.:512-04-9
Totarol inhibits bacterial cytokinesis by perturbing the assembly dynamics of FtsZ.[Pubmed:17348691]
Biochemistry. 2007 Apr 10;46(14):4211-20.
Totarol, a diterpenoid phenol, has been shown to inhibit the proliferation of several pathogenic Gram-positive bacteria including Mycobacterium tuberculosis. In this study, Totarol was found to inhibit the proliferation of Bacillus subtilis cells with a minimum inhibitory concentration of 2 microM. It did not detectably perturb the membrane structure of B. subtilis; it strongly induced the filamentation in B. subtilis cells, suggesting that it inhibits bacterial cytokinesis. Totarol (1.5 microM) reduced the frequency of the Z-ring occurrence per micrometer of the bacterial cell length but did not affect the nucleoid frequency, suggesting that it blocks cytokinesis by inhibiting the formation of the Z-ring. The assembly dynamics of FtsZ is thought to play an important role in the formation and functioning of the Z-ring, a machine that engineers cytokinesis in bacteria. Since Totarol was shown to inhibit the proliferation of M. tuberculosis, we examined the effects of Totarol on the assembly dynamics of M. tuberculosis FtsZ (MtbFtsZ) in vitro. Totarol decreased the assembly of MtbFtsZ protofilaments and potently suppressed the GTPase activity of MtbFtsZ. It bound to MtbFtsZ with a dissociation constant of 11 +/- 2.3 microM. It increased the fluorescence intensity of the MtbFtsZ-1-anilinonaphthalene-8-sulfonic acid complex and inhibited the fluorescence intensity of N-(1-pyrene)maleimide-labeled MtbFtsZ, suggesting that Totarol induces conformational changes in MtbFtsZ. The results indicated that Totarol can perturb the assembly dynamics of FtsZ protofilaments in the Z-ring. Totarol exhibited extremely weak inhibitory effects on HeLa cell proliferation. It did not affect microtubule organization in HeLa cells. The results suggest that Totarol inhibits bacterial proliferation by targeting FtsZ and it may be useful as a lead compound to develop an effective antitubercular drug.
The Synthesis and Antimicrobial Activity of Heterocyclic Derivatives of Totarol.[Pubmed:23119123]
ACS Med Chem Lett. 2012 Aug 28;3(10):818-822.
The synthesis and antimicrobial activity heterocyclic analogs of the diterpenoid Totarol are described. An advanced synthetic intermediate with a ketone on the A-ring is used to attach fused heterocycles and a carbon-to-nitrogen atom replacement is made on the B-ring by de novo synthesis. A-ring analogs with an indole attached exhibit, for the first time, enhanced antimicrobial activity relative to the parent natural product. Preliminary experiments demonstrate that the indole analogs do not target the bacterial cell division protein FtsZ as had been hypothesized for Totarol.
Antibacterial activity of totarol and its potentiation.[Pubmed:1453180]
J Nat Prod. 1992 Oct;55(10):1436-40.
Antimicrobial activity of six diterpenoids isolated from the bark of Podocarpus nagi (Podocarpaceae) has been tested against twelve selected microorganisms. Totarol [1], the most abundant compound among the six, exhibited potent bactericidal activity only against Gram-positive bacteria, among which Propionibacterium acnes was the most sensitive bacterium. Totarol also showed strong activity against four other Gram-positive bacteria tested: Streptococcus mutans, Bacillus subtilis, Brevibacterium ammoniagenes, and Staphylococcus aureus (both penicillin-resistant and penicillin-susceptible strains). The bactericidal activity of Totarol was enhanced when it was tested in combination with several other natural products. Noticeably, the activity of Totarol against Sta. aureus was increased eightfold when tested in combination with 1/2MIC of anacardic acid [9]. The synergistic activity of anacardic acid caused the minimum bactericidal concentration (MBC) of Totarol to be lowered from 1.56 to 0.2 micrograms/ml.
A comprehensive proteomic analysis of totarol induced alterations in Bacillus subtilis by multipronged quantitative proteomics.[Pubmed:25464363]
J Proteomics. 2015 Jan 30;114:247-62.
UNLABELLED: The rapid emergence of microbial drug resistance indicates the urgent need for development of new antimicrobial agents. Bacterial cell division machinery is considered as a promising antimicrobial target. Totarol is a naturally existing diterpenoid, which has the ability to restrain bacterial growth by perturbing the cell division. The present study was conducted to investigate the proteomic alterations in Bacillus subtilis as a consequence of Totarol treatment to decipher its mechanism of action and possible molecular targets. Cellular proteome of the Totarol treated B. subtilis AH75 strain was analyzed by using multiple complementary proteomic approaches. After the drug treatment, 12, 38 and 139 differentially expressed (1.5 fold change) proteins were identified using 2-DE, DIGE and iTRAQ analyses, respectively. In silico functional analysis of the identified differentially expressed proteins indicated a possible effect of Totarol on the central metabolism for energy production, heme biosynthesis and chemotaxis. Interestingly, the primary dehydrogenases, which play a vital role in generating the reducing equivalent, were found to be repressed after Totarol treatment indicating an apparent metabolic shutdown. Consequently, multiple cellular assays including resazurin assay and FACS analysis of 5-cyano-2,3-ditolyl tetrazolium chloride (CTC) staining confirmed the effect of Totarol on respiratory activity and cellular metabolism. BIOLOGICAL SIGNIFICANCE: The exact mechanism of action of Totarol is still unclear and further investigations are essential to identify the molecular/cellular targets of this potential antimicrobial agent. The present study demonstrates the application of differential proteome to decipher the mechanism of action and molecular targets of Totarol in B. subtilis. Our quantitative proteome analysis revealed that Totarol induced alterations in the expression levels of 139 proteins (1.5 fold change and >/=2 peptides) in B. subtilis. Findings obtained from this study indicate that Totarol treatment leads to metabolic shutdown by repressing the major central metabolic dehydrogenases in B. subtilis. In addition, expression levels of universal chaperone proteins, heme biosynthesis, and ribosomal proteins were found to be altered, which caused the filamentation of the bacteria. To the best of our knowledge, this is the foremost inclusive investigation describing Totarol induced alterations in B. subtilis proteome and diverse physiological processes. We anticipate that this in depth proteomic study may contribute to a better understanding of the mode of action of Totarol and its primary molecular and cellular targets.
